Sajazir and Cinryze Comparison

Sajazir®(icatibant)	Cinryze®(C1 esterase inhibitor (human))
Prescription Only SAJAZIR (icatibant) injection is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and...	Prescription Only Cinryze is a synthetic version of a protein found naturally in the bloodstream, which plays a vital role in regulating inflammation in the body. Individuals with a condition known...
Administration
Subcutaneous. Learn more.	Intravenous. Learn more.
Dosing
30 mg injected subcutaneously in the abdominal area. If response is inadequate or symptoms recur, additional injections of 30 mg may be administered at intervals of at least 6 hours. . Learn more.	Adults and Children >12: 1,000 IU Intravenous every 3 or 4 days. Children 6-11: 500 IU Intravenous every 3 or 4 days.. Learn more.
Latin Shorthand
30 mg SC (subcutaneous) in abdomen. If inadequate response or recurring symptoms, administer additional 30 mg injections at ≥6-hour intervals.. Learn more.	Adults and Children >12: 1,000 IU IV q3-4d. Children 6-11: 500 IU IV q3-4d.. Learn more.
Out-Of-Pocket Costs With Copay Card
Learn more.	$0. Learn more.
Annual Cap
Learn more.	$40,000. Learn more.
Assistance Expiration
Learn more.	Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The most commonly reported adverse reactions were injection site reactions, which occurred in almost all patients (97%) in clinical trials. Other common adverse reactions occurring in greater than 1% of patients included pyrexia, transaminase increase, dizziness, and rash. . Learn more.	The most common adverse reactions (≥5%) observed were headache, nausea, rash, vomiting, and fever.. Learn more.
Mechanism of Actions (MoA)
Drugs used in Hereditary Angioedema. Learn more.	Drugs used in Hereditary Angioedema. Learn more.
Special Populations
	1. Is CINRYZE safe to use during pregnancy? There are no specific data available regarding the use of CINRYZE in pregnant women. Animal studies have not been conducted to assess its effects on pregnancy. Whether CINRYZE can cause harm to a developing fetus or affect reproductive capacity in pregnant women is unknown. It should only be administered to a pregnant woman if it is clearly needed. 2. What is the background risk of birth defects and miscarriage in the general U.S. population? In the U.S. general population, the estimated background risk of major birth defects in clinically recognized pregnancies is 2 to 4%, and the risk of miscarriage is estimated to be 15 to 20%. 3. Is there any information on the use of CINRYZE during lactation? There is no available data regarding the presence of CINRYZE in human milk, its effects on breastfed infants, or its impact on milk production. When considering the use of CINRYZE, the benefits of breastfeeding, both for the infant's development and the mother's clinical need, should be weighed against any potential adverse effects on the breastfed child. 4. Has CINRYZE been tested in pediatric patients? Yes, the safety and effectiveness of CINRYZE have been evaluated in pediatric subjects with hereditary angioedema (HAE) aged 7 to 11 years old. Additionally, some subjects under the age of 18 were included in trials, and overall, the safety and tolerability of CINRYZE were found to be similar in pediatric, adolescent, and adult subjects. The pharmacokinetics of CINRYZE were also assessed in pediatric subjects aged 7 to 11 years old. 5. Is CINRYZE suitable for use in geriatric patients? Clinical studies of CINRYZE did not include a sufficient number of subjects aged 65 and over to determine if they respond differently from younger subjects. Reported clinical experience has not identified differences in responses between the elderly and younger patients. Dosing for an elderly patient should be cautious, typically starting at the lower end of the dosing range, considering the higher likelihood of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapies.

Sajazir®(icatibant)

Cinryze®(C1 esterase inhibitor (human))

Prescription Only

SAJAZIR (icatibant) injection is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and...

Prescription Only

Cinryze is a synthetic version of a protein found naturally in the bloodstream, which plays a vital role in regulating inflammation in the body. Individuals with a condition known...

Dosage & Administration

Administration

Subcutaneous. Learn more.

Intravenous. Learn more.

Dosing

30 mg injected subcutaneously in the abdominal area. If response is inadequate or symptoms recur, additional injections of 30 mg may be administered at intervals of at least 6 hours. . Learn more.

Adults and Children >12: 1,000 IU Intravenous every 3 or 4 days. Children 6-11: 500 IU Intravenous every 3 or 4 days.. Learn more.

Latin Shorthand

30 mg SC (subcutaneous) in abdomen. If inadequate response or recurring symptoms, administer additional 30 mg injections at ≥6-hour intervals.. Learn more.

Adults and Children >12: 1,000 IU IV q3-4d. Children 6-11: 500 IU IV q3-4d.. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

Learn more.

$0. Learn more.

Annual Cap

Learn more.

$40,000. Learn more.

Assistance Expiration

Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The most commonly reported adverse reactions were injection site reactions, which occurred in almost all patients (97%) in clinical trials. Other common adverse reactions occurring in greater than 1% of patients included pyrexia, transaminase increase, dizziness, and rash. . Learn more.

The most common adverse reactions (≥5%) observed were headache, nausea, rash, vomiting, and fever.. Learn more.

Mechanism of Actions (MoA)

Drugs used in Hereditary Angioedema. Learn more.

Special Populations

1. Is CINRYZE safe to use during pregnancy?

There are no specific data available regarding the use of CINRYZE in pregnant women. Animal studies have not been conducted to assess its effects on pregnancy. Whether CINRYZE can cause harm to a developing fetus or affect reproductive capacity in pregnant women is unknown. It should only be administered to a pregnant woman if it is clearly needed.

2. What is the background risk of birth defects and miscarriage in the general U.S. population?

In the U.S. general population, the estimated background risk of major birth defects in clinically recognized pregnancies is 2 to 4%, and the risk of miscarriage is estimated to be 15 to 20%.

3. Is there any information on the use of CINRYZE during lactation?

There is no available data regarding the presence of CINRYZE in human milk, its effects on breastfed infants, or its impact on milk production. When considering the use of CINRYZE, the benefits of breastfeeding, both for the infant's development and the mother's clinical need, should be weighed against any potential adverse effects on the breastfed child.

4. Has CINRYZE been tested in pediatric patients?

Yes, the safety and effectiveness of CINRYZE have been evaluated in pediatric subjects with hereditary angioedema (HAE) aged 7 to 11 years old. Additionally, some subjects under the age of 18 were included in trials, and overall, the safety and tolerability of CINRYZE were found to be similar in pediatric, adolescent, and adult subjects. The pharmacokinetics of CINRYZE were also assessed in pediatric subjects aged 7 to 11 years old.

5. Is CINRYZE suitable for use in geriatric patients?

Clinical studies of CINRYZE did not include a sufficient number of subjects aged 65 and over to determine if they respond differently from younger subjects. Reported clinical experience has not identified differences in responses between the elderly and younger patients. Dosing for an elderly patient should be cautious, typically starting at the lower end of the dosing range, considering the higher likelihood of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapies.

Sajazir® Alternatives